doi: 10.3324/haematol.10327.
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Affiliations
- PMID: 17606457
- DOI: 10.3324/haematol.10327
Item in Clipboard
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Haematologica.
2007 Jul.
Free article
Abstract
We investigated the association ofFcgammaRIIIaa and FcgRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcgammaRIIIa and FcgRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcgammaRIIIa and FcgammaRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.
Similar articles
-
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11. Blood. 2006. PMID: 16609067 Clinical Trial.
-
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.Leuk Lymphoma. 2007 Jun;48(6):1102-9. doi: 10.1080/10428190701344881. Leuk Lymphoma. 2007. PMID: 17577773
-
FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.Leuk Lymphoma. 2011 Aug;52(8):1604-6. doi: 10.3109/10428194.2011.574760. Epub 2011 Jun 10. Leuk Lymphoma. 2011. PMID: 21657954 No abstract available.
-
How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.Blood Rev. 2017 Jul;31(4):235-249. doi: 10.1016/j.blre.2017.02.005. Epub 2017 Feb 27. Blood Rev. 2017. PMID: 28262268 Review.
-
[Diffuse large B-cell lymphoma: standard treatment and research questions].Rinsho Ketsueki. 2019;60(9):1193-1198. doi: 10.11406/rinketsu.60.1193. Rinsho Ketsueki. 2019. PMID: 31597843 Review. Japanese.
Cited by
-
ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.Oncotarget. 2017 Apr 6;8(35):58292-58303. doi: 10.18632/oncotarget.16869. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938556 Free PMC article.
-
FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.DNA Cell Biol. 2014 Sep;33(9):616-23. doi: 10.1089/dna.2013.2333. Epub 2014 Jul 22. DNA Cell Biol. 2014. PMID: 25050883 Free PMC article.
-
Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies.Biol Blood Marrow Transplant. 2020 Oct;26(10):1811-1818. doi: 10.1016/j.bbmt.2020.07.014. Epub 2020 Jul 18. Biol Blood Marrow Transplant. 2020. PMID: 32693210 Free PMC article.
-
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.EBioMedicine. 2022 Dec;86:104343. doi: 10.1016/j.ebiom.2022.104343. Epub 2022 Nov 11. EBioMedicine. 2022. PMID: 36371989 Free PMC article.
-
Rituximab resistance.Best Pract Res Clin Haematol. 2011 Jun;24(2):203-16. doi: 10.1016/j.beha.2011.02.009. Epub 2011 Apr 13. Best Pract Res Clin Haematol. 2011. PMID: 21658619 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
